
Oncology NEWS International
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
FDA reviewing sBLA for Pegintron for melanoma
Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma.
KENILWORTH, New JerseySchering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. The agent is currently approved for use in the treatment of chronic hepatitis C. The company said that FDA's Oncology Drugs Advisory Committee will discuss the application at its meeting in March.
Articles in this issue
about 18 years ago
NLST article not balanced, critic of screening trial assertsabout 18 years ago
M.D. Anderson and AstraZeneca form neuropathic pain allianceabout 18 years ago
Good nilotinib responses in imatinib-resistant AP-CMLabout 18 years ago
Virus linked to Merkel cell carcinomaabout 18 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedabout 18 years ago
Recurrence Score helps select node+ pts for chemoabout 18 years ago
For resectable liver mets: Preop chemotherapy or not?about 18 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsabout 18 years ago
MRI shows second-hand smoke damageabout 18 years ago
Assay has high sensitivity for hard-to-detect SLN metsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































